What's new? {#FPar1}
===========

Our study provides the first long-term follow-up data on the use of Absorb BVS in a patient population reflecting daily clinical practice with regard to percutaneous coronary intervention.It is also the first study that reports long-term follow-up data without a previous intervention in dual anti-platelet therapy (DAPT) strategies (prolonging or re-starting).In this patient population, we found that cases of target-vessel failure continued to accrue beyond 2 years after Absorb BVS implantation.Moreover, we found 1 case of very late scaffold thrombosis that occurred 911 days after device implantation in a patient who was not on DAPT.

Introduction {#Sec1}
============

Coronary bioresorbable scaffolds have been developed to overcome the shortcomings of drug-eluting stents (DES). They are designed to provide temporary coronary scaffolding, in order to prevent acute recoil, and allow for vessel healing, and fully resorb over time \[[@CR1]\]. The most widely used bioresorbable scaffold is the Absorb bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, CA, USA), which received CE approval in 2011 and FDA approval in 2016. Initial short-term results of studies conducted with the Absorb BVS were promising, with similar low rates of target-vessel failure (TVF) when compared to metallic DES \[[@CR2]\]. Soon after the Absorb BVS became commercially available, the Amsterdam University Medical Centre---Academic Medical Centre (UMC-AMC) started to implant the Absorb BVS in a 'real-world' population, and started to follow these patients within the context of the AMC Single Centre Real World PCI Registry (hereafter referred as AMC Absorb Registry) \[[@CR3]\]. The 2‑year results of the AMC Absorb Registry showed that the use of Absorb BVS in a patient registry reflecting daily clinical practice was associated with good procedural safety and acceptable clinical outcomes at mid-term (2-year) follow-up \[[@CR4]\]. Higher rates of device thrombosis, however, have been reported up to 3 years after Absorb BVS implantation \[[@CR5], [@CR6]\]. Long-term follow-up after Absorb BVS implantation is therefore necessary in order to examine whether the annual event rates will decline after scaffold dismantling and resorption has been completed. In the current article, we therefore report long-term clinical outcomes of the AMC Absorb Registry.

Methods {#Sec2}
-------

The design of the AMC Absorb Registry, the baseline, the procedural characteristics, the 6‑month clinical outcomes and the 2‑year clinical outcomes, have been reported previously \[[@CR3], [@CR4]\]. Briefly, in the AMC Absorb Registry, all patients who underwent percutaneous coronary intervention (PCI) with Absorb BVS implantation between 30 August 2012 and the 5 August 2013 at the Amsterdam UMC---AMC were included. The decision whether to implant the Absorb BVS was left to the discretion of the operator. We included patients with a wide range of indications, from presentation with stable angina pectoris to presentation with acute coronary syndrome (ACS). The necessity to obtain written informed consent from the included patients was waved by the institutional review committee. All patients received dual anti-platelet therapy (DAPT) for at least 12 months. Clinical follow-up was conducted through telephone contact, and if not possible by live status examination. All reported events were adjudicated by experienced interventional cardiologists (Y. Onuma (Erasmus MC, Rotterdam), P. Suwannasom (Cardialysis B.V., Rotterdam), and M. Beijk (Amsterdam UMC, Amsterdam)).

### Definitions {#Sec3}

The composite endpoint of this analysis was TVF, which was defined as a composite of cardiac death, target-vessel myocardial infarction (TV-MI) and target-vessel revascularisation (TVR). Secondary endpoints were MI, TVR, target-lesion revascularisation and scaffold thrombosis (ScT). All events were defined in accordance with the definitions of the Academic Research Consortium.

### Statistical analysis {#Sec4}

Continuous data are expressed as mean ± standard deviation or as median (interquartile ranges). Dichotomous data are summarised as frequencies (%). Cumulative event rates were estimated using the Kaplan-Meier method. All statistical analyses were performed with SPSS software, version 23 (IBM Corp., Armonk, NY, USA).

Results {#Sec5}
-------

The median follow-up of the study cohort of the AMC Absorb Registry was 1534 days. At the time of the cross-sectional data sweep, the clinical status at 2 years was known in 132 of 135 (97.8%) patients, the clinical status at 3 years in 127 of 135 (94.1%) patients, and the clinical status at 4 years in 124 of 135 patients (91.9%). The baseline characteristics of the population are shown in Tab. [1](#Tab1){ref-type="table"}. We enrolled 135 patients, in whom a total of 159 lesions were treated. Patients were predominantly male (73%); stable angina was the most common indication for PCI (47%). A total of 43 (40%) patients presented with ACS, of whom 17 (13%) presented with ST-elevation myocardial infarction.Table 1Baseline characteristics of the study population*Patient characteristics(n* *=135)*Age (years) 59 ± 11Male sex 98 (73%)Diabetes mellitus 27 (20%)Hypertension 67 (50%)Hypercholesterolaemia 58 (43%)Current smoker 39 (29%)Renal dysfunction 11 (8%)Previous myocardial infarction 34 (25%)Previous PCI 35 (26%)Previous CABG  3 (2%)Multivessel disease 64 (47%)Syntax Score 11.5  (IQ range: 6--17.5)DAPT at discharge135 (100%)-- Acetylsalicylic acid and clopidogrel 42 (31%)-- Acetylsalicylic acid and prasugrel 19 (14%)-- Acetylsalicylic acid and ticagrelor 74 (55%)Indication for PCISTEMI 17 (13%)NSTEMI 36 (27%)Unstable angina 13 (10%)Stable angina 63 (47%)Other  6 (4%)*Lesion characteristics(n* *=159)*Vessels treatedLMCA  2 (1%)LAD 96 (60%)RCx 24 (15%)RCA 37 (23%)Lesion typeA 27 (17%)B1 25 (16%)B2 67 (42%)C 40 (25%)Bifurcation lesions 24 (15%)Ostial lesions  5 (3%)Calcified lesions 18 (11%)Chronic total occlusion 13 (8%)Thrombus present 14 (9%)*PCI* percutaneous coronary intervention, *CABG* coronary artery bypass graft, *IQ* interquartile range, *DAPT* dual antiplatelet therapy, *STEMI* ST-elevation myocardial infarction, *NSTEMI* non-STEMI, *LMCA* left main coronary artery, *LAD* left anterior descending artery, *RCx* ramus circumflex artery, *RCA* right coronary artery

An extensive description of the procedural and lesion characteristics has been published previously \[[@CR7]\]. Briefly, most of the lesions treated with Absorb BVS (67%) were classified as type B2 or C (American Heart Association/American College of Cardiology classification); pre-dilatation was performed in 98% and post-dilatation in 55% of the treated lesions. The Syntax score ranged from 1 to 50, with a medium of 11.5 (interquartile range: 6--17.5). The clinical outcomes of all patients are shown in Tab. [2](#Tab2){ref-type="table"}. At long-term follow-up, the composite endpoint of TVF had occurred in 27 patients. The 4‑year Kaplan-Meier estimate of TVF was 19.8% (Fig. [1](#Fig1){ref-type="fig"}). At 4 years cardiac death had occurred in 4 patients (3.2%) and TV-MI in 9 (6.9%) patients. Definite ScT had occurred in 5 (3.8%) patients. We found 1 case of very late ScT that occurred 911 days after device implantation in a patient who was not on DAPT. A detailed description of the cases with definite ScT is shown in Tab. [3](#Tab3){ref-type="table"}. We found no cases of probable or possible device thrombosis.Table 2Long-term clinical outcomes of the study populationOutcomePatients with an event4‑year cumulative event rateAll-cause mortality10 7.1%Cardiac death 4 3.2%Myocardial infarction14 9.1%Target-vessel myocardial infarction 9 6.9%Target-vessel revascularisation2316.7%Target-lesion revascularisation1814.6%Definite scaffold thrombosis 5 3.8%Probable/possible scaffold thrombosis 0 0%Target-vessel failure2719.8%Fig. 1Kaplan-Meier curve of the outcome of target-vessel failureTable 3Detailed description of the cases of scaffold thrombosisCaseInitial PCI indicationTreated vesselLesion typeCalcificationPre-dilatationPre-dilatation balloonAbsorb size inflation pressurePost-dilatationPost-dilatation balloonOn DAPTTiming (days)TreatmentPossible reason*1*OHCAMid LADANoYes2.5 × 15 mm3.0 × 18 mm (12)Yes2.5 × 15 mm NC (8)Yes  4Thrombus aspirationDistal edge dissectionDistal LADB2NoYes2.5 × 15 mm3.0 × 28 mm (14)Yes2.5 × 15 mm NC (10)Xience 3.0 × 38 mmXience 3.0 × 18 mm*2*NSTEMIProximal LADB2NoNo--2.5 × 18 mm (16)No--Yes  8Thrombus aspirationXience 2.5 × 28 mmIncomplete expansion distal part of scaffold*3*Unstable APDistal LADB1NoYes2.5 × 15 mm2.5 × 28 mm (24)Yes2.5 × 15 mm NC (24)No 24Thrombus aspirationXience 2.5 × 28 mmDAPT cessation*4*NSTEMIProximal RCxB1NoYes2.5 × 15 mm3.5 × 28 mm (10)Yes3.5 × 16 mm NC (16)No112Thrombus aspiration multiple balloon inflationsDAPT cessation*5*Stable APProximal RCAANoYes2.5 × 15 mm3.0 × 18 mm (10)No--No911Azule 3.0 × 23 mmDAPT cessation, intraluminal scaffold dismantling*OHCA* out-of-hospital cardiac arrest, *LAD* left anterior descending artery, *NC* non-compliant, *NSTEMI* non-ST-elevation myocardial infarction, *AP* angina pectoris, *DAPT* dual antiplatelet therapy, *RCx* ramus circumflex artery, *RCA* right coronary artery

Discussion {#Sec6}
----------

In the AMC Absorb Registry, the composite endpoint of TVF continued to accrue beyond 2 years after Absorb BVS implantation. Additionally, we found 1 case of very late ScT that occurred 911 days after device implantation in a patient who was not on DAPT. Absorb BVS was initially expected to be fully resorbed at 2 years after device implantation. Several studies have, however, reported that (very) late ScT also frequently occurs between the 2nd and 3rd year after device implantation, and even beyond 3 years, with the latest case of ScT reported as late as 44 months after Absorb BVS implantation \[[@CR5], [@CR6], [@CR8], [@CR9]\]. In these studies, the leading mechanisms of very late ScT were associated with (disintegrated) strut material that protruded into the coronary lumen, most likely as a consequence of intraluminal scaffold dismantling or late (acquired) malapposition \[[@CR10]\]. DAPT is hypothesised to be an important factor in the prevention of thrombotic events after coronary stent implantation. When the preliminary safety report of the Amsterdam Investigator-initiateD Absorb Strategy All-comers (AIDA) trial (an international, multicentre, randomised trial in which the BVS was compared to DES) was published due to safety concerns regarding device thrombosis, the AIDA steering committee recommended cardiologists to consider re-starting or prolonging DAPT in patients treated with Absorb BVS up to 3 years after device implantation \[[@CR11]\]. At that time point, all patients in the AMC Absorb Registry were already beyond 3 years after Absorb BVS implantation, so there was no additional medical intervention in this group, unlike in the AIDA trial. At 4‑year follow-up, in the AMC Absorb Registry, the estimated definite ScT rate was 3.8%, whereas in the comparable AIDA population the definitive ScT rate was 3.3% at 3 years. To date, it remains uncertain whether prolonged DAPT actually prevents (very late) ScT. Notably, in a large meta-analysis, 92% of the cases of very late ScT occurred in patients that were not on DAPT at the time of the event \[[@CR12]\].

One of the causes hypothesised to be a (major) contributor to the adverse outcomes of Patients treated with Absorb BVS was suboptimal Absorb BVS implantation techniques. Optimised Absorb BVS implantation techniques, generally based on a pre-dilatation, sizing and post-dilatation (PSP) strategy were thereafter hypothesised to optimise outcomes after Absorb BVS implantation. The most correct definition of correct PSP implantation remains unknown, however, and its effect on the improvement of outcomes remains cumbersome and varies between studies \[[@CR13]--[@CR16]\]. Moreover, while suboptimal implantation techniques might explain (acute and early) events up to 3 years after implantation, it is difficult to stipulate that implantation techniques at the initial procedure impact outcomes at 4--5 years after device implantation, since the complex, and sometimes unpredictable and irregular, resorption process of the device occurs during this period.

In the ABSORB II trial, a downturn of events has been reported between the 3rd and 4th year of follow-up, thereby positively impacting the difference between the target-lesion failure rates of Absorb BVS and Xience EES at 4‑year follow-up \[[@CR17]\]. Moreover, within the ABSORB III trial, in contrast to the pattern observed before 3 years, the event rates were similar between the Absorb BVS and Xience EES groups after 3 years \[[@CR18]\]. The downturn in device-related events beyond 3 years after implantation in Absorb BVS patients within the ABSORB II and ABSORB III trials is encouraging. However, in the ABSORB II and ABSORB III trials, the patient populations were selected. In ABSORB II, patients that presented with an MI were excluded; and unstable patients and those with complex lesions were excluded from ABSORB III \[[@CR19], [@CR20]\].

Long-term follow-up, with precisely documented and investigated DAPT regimens/strategies, of large randomised studies such as the AIDA and the ABSORB IV trial, is therefore necessary in order to establish whether the annual rates of device-related-events in patients treated with Absorb BVS in routine clinical practice will decline after the period of complete scaffold dismantling and resorption.

### Study limitations {#Sec7}

This study is a registry, and therefore a control group is lacking. Second, the decision whether to implant an Absorb BVS was left to the discretion of the operator, and therefore potential patient selection bias has been introduced. Finally, routine intracoronary imaging has not been performed, and therefore potential information on the mechanism of scaffold failure might have been missed.

Conclusion {#Sec8}
==========

In a patient population reflecting routine clinical practice, we found that cases of TVF continued to accrue beyond 2 years after Absorb BVS implantation.
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